MURRAY HILL, N.J., Jul 24, 2003 (BUSINESS WIRE) -- C. R. Bard,
Inc. (NYSE:BCR) today announced that it has acquired assets related to
the manufacture and distribution of a new biopsy device from BIP
Biomedical Instruments and Products GmbH (BIP), located in Turkenfeld,
Germany. Bard Peripheral Vascular, Inc., Bard's subsidiary located in
Tempe, Arizona, will market the product. Terms of the transaction were
The new minimally invasive device has a proprietary
vacuum-assisted design. It is initially targeted at breast biopsies,
for which there are an estimated 2.3 million procedures performed
annually around the world. Approximately half of these procedures are
performed using less invasive biopsy devices with the balance done
surgically. Bard's new biopsy product is a self-contained, portable
unit that fits into the physician's hand, providing optimal control,
accuracy and flexibility for biopsy procedures. The device is suitable
for use with a range of imaging technologies including stereotactic
x-ray and ultrasound. In 1995, Bard acquired BIP's Magnum(R) core
needle biopsy device, which is the current market leader for
spring-loaded core needle biopsies.
William H. Longfield, chairman and chief executive officer,
commented, "This acquisition leverages our market leadership position
in core needle biopsy, enabling us to enter the larger and faster
growing vacuum-assisted segment. It is consistent with our objective
to acquire early stage technology to enhance our franchises and
improve our sales growth."
The company said that this transaction does not change its
guidance for 2003.
This press release contains forward-looking statements, the
accuracy of which is necessarily subject to risks and uncertainties.
Please refer to our March 31, 2003, Form 10-Q for a statement with
regard to forward-looking statements, including disclosure of
additional factors that could cause actual results to differ
materially from those expressed or implied.
C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer, and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology and surgical specialty products.
SOURCE: C. R. Bard, Inc.
C. R. Bard, Inc., Murray Hill
Eric J. Shick, 908-277-8413
Holly P. Glass, 703-754-2848
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.